HDAC2 as a target for developing anti-cancer drugs

Histone deacetylases (HDACs) deacetylate histones H3 and H4. An imbalance between histone acetylation and deacetylation can lead to various diseases. HDAC2 is present in the nucleus. It plays a critical role in modifying chromatin structures and regulates the expression of various genes by functioni...

Descripción completa

Detalles Bibliográficos
Autores principales: Jo, Hyein, Shim, Kyeonghee, Kim, Han-Ul, Jung, Hyun Suk, Jeoung, Dooil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Research Network of Computational and Structural Biotechnology 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030825/
https://www.ncbi.nlm.nih.gov/pubmed/36968022
http://dx.doi.org/10.1016/j.csbj.2023.03.016
_version_ 1784910462354194432
author Jo, Hyein
Shim, Kyeonghee
Kim, Han-Ul
Jung, Hyun Suk
Jeoung, Dooil
author_facet Jo, Hyein
Shim, Kyeonghee
Kim, Han-Ul
Jung, Hyun Suk
Jeoung, Dooil
author_sort Jo, Hyein
collection PubMed
description Histone deacetylases (HDACs) deacetylate histones H3 and H4. An imbalance between histone acetylation and deacetylation can lead to various diseases. HDAC2 is present in the nucleus. It plays a critical role in modifying chromatin structures and regulates the expression of various genes by functioning as a transcriptional regulator. The roles of HDAC2 in tumorigenesis and anti-cancer drug resistance are discussed in this review. Several reports suggested that HDAC2 is a prognostic marker of various cancers. The roles of microRNAs (miRNAs) that directly regulate the expression of HDAC2 in tumorigenesis are also discussed in this review. This review also presents HDAC2 as a valuable target for developing anti-cancer drugs.
format Online
Article
Text
id pubmed-10030825
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Research Network of Computational and Structural Biotechnology
record_format MEDLINE/PubMed
spelling pubmed-100308252023-03-23 HDAC2 as a target for developing anti-cancer drugs Jo, Hyein Shim, Kyeonghee Kim, Han-Ul Jung, Hyun Suk Jeoung, Dooil Comput Struct Biotechnol J Review Article Histone deacetylases (HDACs) deacetylate histones H3 and H4. An imbalance between histone acetylation and deacetylation can lead to various diseases. HDAC2 is present in the nucleus. It plays a critical role in modifying chromatin structures and regulates the expression of various genes by functioning as a transcriptional regulator. The roles of HDAC2 in tumorigenesis and anti-cancer drug resistance are discussed in this review. Several reports suggested that HDAC2 is a prognostic marker of various cancers. The roles of microRNAs (miRNAs) that directly regulate the expression of HDAC2 in tumorigenesis are also discussed in this review. This review also presents HDAC2 as a valuable target for developing anti-cancer drugs. Research Network of Computational and Structural Biotechnology 2023-03-13 /pmc/articles/PMC10030825/ /pubmed/36968022 http://dx.doi.org/10.1016/j.csbj.2023.03.016 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review Article
Jo, Hyein
Shim, Kyeonghee
Kim, Han-Ul
Jung, Hyun Suk
Jeoung, Dooil
HDAC2 as a target for developing anti-cancer drugs
title HDAC2 as a target for developing anti-cancer drugs
title_full HDAC2 as a target for developing anti-cancer drugs
title_fullStr HDAC2 as a target for developing anti-cancer drugs
title_full_unstemmed HDAC2 as a target for developing anti-cancer drugs
title_short HDAC2 as a target for developing anti-cancer drugs
title_sort hdac2 as a target for developing anti-cancer drugs
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030825/
https://www.ncbi.nlm.nih.gov/pubmed/36968022
http://dx.doi.org/10.1016/j.csbj.2023.03.016
work_keys_str_mv AT johyein hdac2asatargetfordevelopinganticancerdrugs
AT shimkyeonghee hdac2asatargetfordevelopinganticancerdrugs
AT kimhanul hdac2asatargetfordevelopinganticancerdrugs
AT junghyunsuk hdac2asatargetfordevelopinganticancerdrugs
AT jeoungdooil hdac2asatargetfordevelopinganticancerdrugs

Ejemplares similares